THE CORES A SYMPTOM-MODIFYING PREPARATIONS OF THE SLOWEDDOWN ACTION   IN THERAPY OF OSTEOARTROSIS

V V Badokin; V V Badokin

doi:10.14341/osteo2010128-33

THE CORES A SYMPTOM-MODIFYING PREPARATIONS OF THE SLOWEDDOWN ACTION IN THERAPY OF OSTEOARTROSIS

V V Badokin, V V Badokin

https://doi.org/10.14341/osteo2010128-33

Abstract

Osteoarthritis is the most common disorders of the locomotor system. This is multifaktor disorder and the inflammation in the bones and cartilage, synovial envelope and subhondral bone play the important role in the pathogenesis of osteoarthritis. The main symptom-modified drugs are glikozamin sulfate and chondroitine sulfate, which have a high degree of evidence. These agents not only suppress pain and normalize function affected joints but also slowed progression of osteoarthritis, normalize and stabilize the structural changes in gyaline cartilage, warn changes in noninvolved joint. Theraflex is combined and includes both basic structural modifier cartilage. It has all the properties that are called chondroprotektive drugs.

Keywords

Osteoartrosis, glucosamine sulfate, Chondroitin Sulfate, Theraflex

About the Authors

V V Badokin

References

1. Алексеева Л.И. Симптоматические препараты замедленного действия при лечении ОА. Consilium medicus 2009; 11 (9): 100-104.

2. Бадокин В.В. Значение воспаления в развитии и течении остеоартроза. Consilium medicus 2009; 11(9): 91-95.

3. Беневоленская Л.И., Алексеева Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных остеоартрозом коленных и тазобедренных суставов. РМЖ 2005; 8: 525-527.

4. Кригштейн О.С., Голубев Г.Ш. Оценка доказательств эффективности средств, претендующих называться «структурно-модифицируюими препаратами», 2004-2007 гг. Клинич. фармакология и фармакоэкономика 2008; 1: 55-88.

5. Лила A.M., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ 2007; 13 (24): 1618-1622.

6. Поворознюк В.В. Глюкозамин и хондроитин в лечении остеоартроза: данные литературы и результаты собственных исследований. РМЖ 2006; 14 (4): 290-294.

7. Brandt KD. Diagnosis and nonsurgical management of osteoarthritis. Proffessional communications, 2000.

8. Bruyere O, Pavelka K, Rovati LC et al. Total joint replacement after glucosamine sulphate treatment in rnee ostheoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16 (2): 254-260.

9. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulphate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795-808.

10. Herrero-BeaumontG, Rovati LC. Use of crystalline glucosamine sulphate in osteoarthritis. Future Rheumatol 2006; 1 (4): 397-414

11. . Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach.

Review

For citations:

Badokin V.V., Badokin V.V. THE CORES A SYMPTOM-MODIFYING PREPARATIONS OF THE SLOWEDDOWN ACTION IN THERAPY OF OSTEOARTROSIS. Osteoporosis and Bone Diseases. 2010;13(1):28-33. https://doi.org/10.14341/osteo2010128-33

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Osteoporosis and Bone Diseases